Summary: Galactosyl hydroxylysine and deoxypyridinoline are at present the most promising markers of bone resorption. Various studies have indeed shown that these two markers discriminate with high accuracy subjects with different rates of bone turnover and that their accuracies and discriminate power are very similar. The aim of this paper is to compare the practicality and the reproducibility of the HPLC galactosyl hydroxylysine and deoxypyridinoline assays.
Introduction
. , . , . . the techniques used to measure these two markers Because of the importance of bone resorption in the with particular emphasis on their practicality and pathogenesis of bone diseases, there is an increasing their reproducibility. demand for non-invasive techniques for the rapid and easy detection of changes in the rate of this process. Biochemical markers are certainly adequate for this Rationale for the Use of Galactosyl Hydroxylysine and purpose, and the last decade has seen the development Deoxypyridinoline as Markers for Bone Resorption of new markers that appear to be specific for bone ^ which, m addition to bone, is also present in other nary excretion of different products of collagen break-. . , ' . . . j ,«'. ,· f i t j 7 · j connective tissues, such as skin, is a heterotrumer down (hydroxyprolme, galactosyl hydroxylysine and Γ , , /τ \ ι · Λ ι · * i j j , -j. f. v formed by two a,(I)-chams and one α-,-chain folded deoxypyridinoline). ^ ., . ·,,,. τ , ι." ι ι · together in a triple helix. In bone this molecule is This review of the present knowledge of galactosyl produced by the osteoblasts and deposited in a highly hydroxylysine and deoxypyridinoline also compares organized manner in the matrix (for a review on collagen synthesis see I.e. (1, 2) .
tions both inside and outside the cell. While no differences exist in the primary structure of the type 1 collagen deposited in different connective tissues, the post-translational modifications are, to different extents, tissue-specific (1).
After the pro-oc-chains have entered the endoplasrnic cisternae, approximately 100 proline and ten lysine residues in every chain are hydroxylated by specific enzymes to hydroxyproline and hydroxylysine. Furthermore, either a galactose or a glucose-galactose is attached to approximately one third of the hydroxylysine residues by specific transferases, forming galactosyl hydroxylysine and glucosyl-galactosyl hydroxylysine. As soon as at least 90 proline residues are converted to hydroxyprolines, two pro-oci(I)-chains and one pro-a 2 -chain fold together, an event which inhibits any further transformation and results in the formation of type 1 procollagen.
The procollagen molecule is then excreted by the cell into the extracellular space where the two non-helical extensions, called N-and C-terminal procollagen peptides, are cleaved off by two specific peptidases. The new collagen thus formed is then inserted in the existing matrix and some of the lysines are oxidatively deaminated by lysyl oxidase. Finally, the oxidized lysines form reducible and non-reducible crosslinks within and between the collagen molecules.
Because the products of these post-translational modifications show a certain tissue specificity, and are released and excreted in the urine during the collagen breakdown, they have been proposed as markers of bone resorption.
Hydroxyproline: The Time-Honoured Marker of Bone Resorption
Determination of the urinary excretion of hydroxyproline is the most commonly used routine clinical assay for the measurement of bone resorption.
However, hydroxyproline is not specific for bone collagen, since together with proline and alanine it is the most abundant amino acid (except for glycine) in all collagen molecules (3). In addition, hydroxyproline is present in all molecules that have a collagen-like structure, such as Clq component of complement (4).
Moreover, urinary hydroxyproline excretion cannot be used to quantify the rate of collagen breakdown, since about 80% of hydroxyproline released during this process is metabolized in the liver to H 2 O and CO 2 (5, 6) , and a fraction of the hydroxyproline (perhaps 10%) that is detectable in urine is derived from newly synthesized procollagen peptides (7) and new collagen which is degraded before being deposited in the matrix (8) .
Galactosyl Hydroxylysine and Deoxypyridinoline: Two New Specific Markers of Bone Resorption
In recent years two different products of collagen breakdown have been proposed as specific markers of bone resorption. These molecules are products of intracellular (galactosyl hydroxylysine) and extracellular (deoxypyridinoline) post-translational collagen modifications.
Hydroxylysine glycosides are specific for collagen. Although the fraction of hydroxylysine residues that are glycosylated does not differ in skin or bone (these are the major sources of type 1 collagen in the human body) the pattern of hydroxylysine glycosylation is different in these two tissues. Thus glucosyl-galactosyl hydroxylysine predominates in the skin, where the ratio between glucosyl-galactosyl hydroxylysine and galactosyl hydroxylysine (glucosyl-galactosyl hydroxylysine/galactosyl hydroxylysine) is approximately 2 (9), whereas galactosyl hydroxylysine predominates in bone, where the glucosyl-galactosyl hydroxylysine/galactosyl hydroxylysine ratio is 0.47 (10).
This pattern of glycosylation, moreover, does not seem to vary in the presence of increased bone turnover, since the glucosyl-galactosyl hydroxylysine/galactosyl hydroxylysine ratio in bone collagen is not altered in Page f 's disease of bone (10) . Recently some concerns have been expressed on the possibility of a conversion of glucosyl-galactosyl hydroxylysine to galactosyl hydroxylysine by a kidney oc-glucosidase demonstrated in the rat (lOb). However, Moro et al. have recently demonstrated that no a-or ß-glycosidases exist in the human kidney, so that glucosylgalactosyl hydroxylysine and galactosyl hydroxylysine are indeed the final products of collagen degradation in humans (lOc) .
Finally the hydroxylysine glycosides do not undergo any major liver metabolism and their urinary excretion is not influenced by the diet (10, 11, lib).
The pyridinium crosslink, i. e. pyridinoline, also called hydroxylysyl-pyridinoline, and deoxypyridinoline, also named lysyl-pyridinoline, are the most important non-reducible crosslinks of mature bone collagen.
Pyridinoline is the most abundant of the pyridinium crosslinks and is present in different connective tissues, including bone, with tte* highest concentration in cartilage (12) . Deoxypyridinoline, on the other hand, has been detected only in bone and dentine, where its concentration is approximately one fourth of that of pyridinoline (12) .
Studies in animals have shown that the amount of pyridinoline and deoxypyridinoline in bone is not constant and varies with the extent of mineralization (14, 15) and the oestrogen status (16), increases with age (17) and is different in trabecular and cortical bone (13) .
Both crosslinks are released into the bloodstream after collagen break down, and are then excreted in the urine where their concentration can be measured.
Because of the different pattern of hydroxylysine glycosylation and because deoxypyridinoline is present only in bone and dentine and since both these molecules do not undergo any major liver metabolism, the urinary excretion of galactosyl hydroxylysine and deoxypyridinoline has been proposed for the estimation of the rate of bone resorption.
In recent years, some clinical studies have compared the clinical performances of these bone resorption assays (18 -20) . The results of these studies, which are summarized in table la and Ib, show that the clinical performances of galactosyl hydroxylysine and I deoxypyridinoline are very similar in different patient • populations. Moreover, in all the clinical conditions I evaluated so far, there is no indication that one marker is superior to the other. On the other hand, some data suggest that the use of the two markers together may provide better differentiation of the pathological from the normal condition (19, 20) .
Galactosyl Hydroxylysine and Deoxypyridinoline: A Methodological Comparison
Since more and more data seem to demonstrate a high similarity in clinical performances of galactosyl hydroxylysine and deoxypyridinoline, we wanted to compare the different methodologies used to measure galactosyl hydroxylysine and deoxypyridinoline and to evaluate any differences in their practicality and reproducibility.
Both galactosyl hydroxylysine and deoxypyridinoline are measured by high performance liquid chromatography (HPLC) using fluorescence as a signal (12, 21) . While deoxypyridinoline is naturally fluorescent, galactosyl hydroxylysine is not, therefore a derivatization with a fluorescent molecule is needed prior to the chromatography.
Methods

Preanalytical procedures
Deoxypyridinoline
The pyridinium crosslinks are present in the urine both free and in the form of peptides of different molecular mass (22) . For this reason an acid hydrolysis is needed prior to the injection into the HPLC (tab. 2). Due to the very low urine concentration of pyridinoline and deoxypyridinoline (nmol/1) a preextraction is also needed.
Galactosyl hydroxylysine
Galactosyl hydroxylysine in urine is all in a free form (22b), so that no hydrolysis is needed. Furthermore the galactosyl hy- Pagefs disease and children were compared with normal adults (n = 22). Osteoporosis 1 were compared with normal premenopausal women (n = 11). The correlation between galactosyl hydroxylysine and deoxypyridinoline was r = 0.859, p < 0.001, n = 51 (18) . Osteoporosis 2 were compared with postmenopausal controls (n = 32) (19) .
Tab. Ib. Similarities in clinical performances between galactosyl hydroxylysine (mmol/mol of creatinine) and deoxypyridinoline (μΐϊΐοΐ/mol of creatinine) derived from our unpublished data. The excretion of the two markers was measured in patients with Ullrich-Turner syndrome before and after treatment with a low (2 U/m 2 · d) (n. = 11) and a high (3 U/m 2 · d) (n = 9) dose of somatotropin (growth hormone). All the results are highly significant p < 0.001. droxylysine urinary concentration (μιηοΐ/ΐ) is higher than those of pyridinoline and deoxypyridinoline, so that no preextraction is needed. On the other hand, as mentioned above, galactosyl hydroxylysine is not naturally fluorescent, and must therefore be derivatized with a fluorescent molecule. The molecule used for this purpose is dansyl chloride (tab. 3). Due to steric hindrance, glucosyl-galactosyl hydroxylysine is mainly mono-dansylated, whereas galactosyl hydroxylysine reacts with two dansyl chloride molecules (23, 23b) .
Galactosyl hydroxylysine Deoxypyridinoline
Bettica et
al.: Galaclosyl hydroxylysine and deoxypyridinoline as bone resorption markers Tab. 2. Deoxypyridinoline: procedures prior to injection
Analytical procedures
Deoxypyridinoline
The two pyridinium crosslinks are separated on a reverse phase column (C, 8 ) using either a gradient (12) or an isocratic (24) chromatography.
Both the gradient and isocratic chromatography use an aqueous buffer with ammonium chloride (0.02 mol/1), EDTA (0.5 mmol/1) and w-heptafluoro butyric acid (0.01 mol/1) as the ionpairing agent (solvent A, pH 2.0) and acetonitrile as a hydrophobic agent (solvent B).
The pyridinoline and deoxypyridinoline concentrations are calculated by means of external pyridinoline and deoxypyridinoline standards, which are extracted either from bone or urine.
Galactosyl hydroxylysine
Galactosyl hydroxylysine is separated from the other molecules on a reverse phase column (C, 8 ) using gradient.chromatography (21) . The aqueous buffer is 0.05 mol/1 acetic acid, 125 ml/1 acetonitrile and 50 ml/l propan-2-ol, pH 6.3 (buffer A) and the hydrophobic buffer is 0.05 mol/1 acetic acid, 500 ml/1 acetonitrile and 10 ml/l propan-2-ol, pH 6.5 (buffer B).
The external standard used to calculate the galactosyl hydroxylysine concentration is L-lysine. L-Lysine was chosen (instead of ZMysine or hydroxylysine) because, like galactosyl hydroxylysine, it reacts with two molecules of dansyl chloride, therefore giving only one peak on the chromatogram, corresponding to the didansyl derivative of L-lysine.
The preanalytical and analytical pi;cicedures for galactosyl hydroxylysine and deoxypyridinoline are summarized and compared on To compare the reproducibility of the two assays we collected 24-hour urine samples from two normal adults (A and B). During the 24 hours of urine collection, subject A followed a diet rich in fluids while subject B followed a normal diet. Sample A was used as a low control, and sample B was considered a medium control. Galactosyl hydroxylysine was measured by the method of Moro et al, (21) , while deoxypyridinoline was measured by the method of Kamel et al. with minor modifications (24) . To calculate the intra-assay variation we tested samples A and B in 4-6 replicates. The test was repeated on 4 different days and the intra-assay variation was calculated as the mean ± SD of the intra-assay coefficient of variation of each» day. To calculate the inter-assay variation we tested sample A and B on 7 sequential days.
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Tab. 5. Galactosyl hydroxylysine and deoxypyridinoline concentration (mean ± standard deviation) and intra-assay and interassay variation of the two measurements
Galaclosyl hydroxylysine Deoxypyridinoline
Infra-assay variation
Sample A n Mean ± SD CV Sample B n Mean ± SD CV
Infer-assay variation
Sample A n Mean ± SD CV Sample B n Mean ± SD CV 
Reproducibility Results
The results are reported in table 5. Galactosyl hydroxylysine showed a lower intra-assay variation than deoxypyridinoline with a coefficient of variation (CV) ranging from 4.6 ±1.7 (Sample A) to 4.7 ±1.5 (Sample B) for galactosyl hydroxylysine and from 8.4 ± 4.8 (Sample A) to 9.2 ± 1.8 (Sample B) for deoxypyridinoline. Similarly, the inter-assay variation was much lower for galactosyl hydroxylysine than for deoxypyridinoline. The galactosyl hydroxylysine inter-assay CV ranged from 8.3% (Sample A) to 6.7% (Sample B), while the deoxypyridinoline inter-assay CV ranged from 17.5% (Sample A) to 11.5% (Sample B).
Discussion
Both galactosyl hydroxylysine and deoxypyridinoline fulfil the requirements for a specific marker for bone resorption. Both the molecules are, in fact, relatively specific for bone, none of them is reutilized after the collagen breakdown and both of them seem to be excreted unchanged in the urine (9 -12) . All the clinical studies that have compared their clinical performances have indeed shown that galactosyl hydroxylysine and deoxypyridinoline are highly correlated, have similar accuracy and discriminatory power in distinguishing subjects with altered bone resorption from normal subjects (18) (19) (20) . In the present study, the methods for galactosyl hydroxylysine and deoxypyridinoline determination were compared.
In addition to the similar clinical value of the two quantities, the analytical procedures for galactosyl hydroxylysine and deoxypyridinoline also show many similarities. Both molecules, for example, are measured by means of an HPLC system and detected by fluorescence. An immunoenzymatic test has also been proposed for deoxypyridinoline (22a). However, because of the high similarity between deoxypyridinoline and pyridinoline (the other pyridinium crosslink that is not bone-specific) the immunoenzymatic test responds to both of these molecules, so that only the HPLC procedure guarantees the exclusive measurement of deoxypyridinoline.
Methodologically, the methods for galactosyl hydroxylysine and deoxypyridinoline differ mainly in the preanalytical procedures. Galactosyl hydroxylysine does not need to be hydrolyzed and extracted since this molecule is present in free form in the urine (22b).
On the other hand, since galactosyl hydroxylysine is not fluorescent, it must be derivatized with dansyl chloride. In contrast, deoxypyridinoline is naturally fluorescent. However, in urine, almost 50% of this molecule is in the form of peptides of different molecular mass (22) . For this reason an acid hydrolysis and an extraction is needed prior to the injection into the HPLC. The need for a hydrolysis and a preextraction in the measurement of deoxypyridinoline implies two problems:
2) error due to the recovery.
Time
As shown in table 3c, 36-48 hours are needed for deoxypyridinoline preanalytical procedures (calculated for 20 samples) while only 2 -3 hours are needed for the galactosyl hydroxylysine derivatization (calculated for 20 samples). For this reason, the determination of deoxypyridinoline as a routine clinical procedure would require either a full-time technician or some kind of automation. An automated liquid solid extraction procedure for the pyridinium crosslinks has been recently proposed and the ability to extract 60 samples in 9 hours has been claimed by the authors (25) . If confirmed, this procedure may represent a significant improvement to this important inconvenience in the pyridinium crosslinks measurement.
Recovery
The most important problem of pre-extraction, however, is the risk of error due to variable recovery of the samples. In our study both the intra-assay and inter-assay variations of deoxypyridinoline were 50-100% higher than those shown for galactosyl hydroxylysine. These variations were due to the preextraction since the reproducibility for galactosyl hydroxylysine and deoxypyridinoline HPLC procedures were similar (data not shown). An appropriate internal standard is frequently used to control this important source of variation. Recently Colwell et al. (26) have proposed iso-desmosine as a possible internal standard for the pyridinium crosslinks extraction, since this molecule has a different elution time on HPLC, but behaves like the pyridinium crosslinks towards the heat and the acid environment (26) . Further studies are needed to confirm that the use of isodesmosine as an internal standard can decrease the important variation demonstrated so far for the deoxypyridinoline HPLC measurement.
As mentioned above, the analytical procedures for galactosyl hydroxylysine and deoxypyridinoline are similar. The HPLC analysis of deoxypyridinoline is, however, more rapid (because of the preextraction), and isocratic elution conditions can be used. Moreover, the preextraction allows the injection of a purer sample into the HPLC, and more runs can therefore be made on the same column for the deoxypyridinoline measurement. The analytical procedures of both galactosyl hydroxylysine and deoxypyridinoline can be easily automated by using an HPLC system with an autosampler and a computer.
In conclusion we have reviewed our knowledge of galactosyl hydroxylysine and deoxypyridinoline with particular emphasis on the practicality and the reproducibility of their measurements, and we have shown that the major differences between galactosyl hydroxylysine and deoxypyridinoline assays are the preanalytical hydrolysis and an extraction, which must be performed before the deoxypyridinoline assay. The deoxypyridinoline measurement consequently requires longer time for its operation, and its recovery is more variable.
